Disease origin and progression in amyotrophic lateral sclerosis: An immunology perspective

International Immunology

Volumn 27, Issue 3, 2015, Pages 117-129

  Malaspina, Andrea ^a   Puentes, Fabiola ^a   Amor, Sandra ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Innate immunity; Microglia; Neurodegeneration; Neuroinflammation; Therapy

Indexed keywords

ANTIGEN; AUTOANTIBODY; BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTROCYTE; DISEASE COURSE; EXPERIMENTAL MODEL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGY; MICROGLIA; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; ANIMAL; DISEASE MODEL; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY; MOTONEURON; NEUROGENIC INFLAMMATION; PATHOLOGY; PHYSIOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; MICROGLIA; MOLECULAR TARGETED THERAPY; MOTOR NEURONS; NEUROGENIC INFLAMMATION; NEUROMUSCULAR JUNCTION;

EID: 84929612769     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxu099     Document Type: Article

References (176)

1. Rowland, L. P. 2001. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch. Neurol. 58:512.
2. Strong, M. J., Hudson, A. J. and Alvord, W. G. 1991. Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature. Can. J. Neurol. Sci. 18:45.
3. Chance, P. F., Rabin, B. A., Ryan, S. G. et al. 1998. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am. J. Hum. Genet. 62:633.
4. Roche, J. C., Rojas-Garcia, R., Scott, K. M. et al. 2012. A proposed staging system for amyotrophic lateral sclerosis. Brain 135:847.
5. Hardy, J. and Rogaeva, E. 2014. Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp. Neurol. 262:75.
6. Zago, S., Poletti, B., Morelli, C., Doretti, A. and Silani, V. 2011. Amyotrophic lateral sclerosis and frontotemporal dementia (ALSFTD). Arch. Ital. Biol. 149:39.
7. Seelaar, H., Schelhaas, H. J., Azmani, A. et al. 2007. TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain 130:1375.
8. Rosen, D. R. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364:362.
9. Neumann, M., Sampathu, D. M., Kwong, L. K. et al. 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130.
10. Kwiatkowski, T. J., Jr, Bosco, D. A., Leclerc, A. L. et al. 2009. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205.
11. Kiernan, M. C., Vucic, S., Cheah, B. C. et al. 2011. Amyotrophic lateral sclerosis. Lancet 377:942.
12. Leblond, C. S., Kaneb, H. M., Dion, P. A., and Rouleau, G. A. 2014. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 262:91.
13. Turner, M. R. 2011. MRI as a frontrunner in the search for amyotrophic lateral sclerosis biomarkers? Biomark. Med. 5:79.
14. Turner, M. R., Grosskreutz, J., Kassubek, J. et al. 2011. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. 10:400.
15. Krakora, D., Macrander, C. and Suzuki, M. 2012. Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis. Neurol. Res. Int. 2012:379657.
16. Kiernan, J. A. and Hudson, A. J. 1991. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 114:843.
17. Körner, S., Kollewe, K., Fahlbusch, M. et al. 2011. Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis. Muscle Nerve 43:636.
18. Turner, M. R., Kiernan, M. C., Leigh, P. N. and Talbot, K. 2009. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 8:94.
19. Amor, S., Puentes, F., Baker, D. and van der Valk, P. 2010. Inflammation in neurodegenerative diseases. Immunology 129:154.
20. Amor, S., Peferoen, L. A., Vogel, D. Y. et al. 2014. Inflammation in neurodegenerative diseases-an update. Immunology 142:151.
21. Parakh, S., Spencer, D. M., Halloran, M. A., Soo, K. Y. and Atkin, J. D. 2013. Redox regulation in amyotrophic lateral sclerosis. Oxid. Med. Cell. Longev. 2013:408681.
22. Pasinelli, P. and Brown, R. H. 2006. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7:710.
23. Brettschneider, J., Toledo, J. B., Van Deerlin, V. M. et al. 2012. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 7:e39216.
24. Kawamata, T., Akiyama, H., Yamada, T. and McGeer, P. L. 1992. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140:691.
25. McGeer, P. L. and McGeer, E. G. 2002. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26:459.
26. Beers, D. R., Zhao, W., Liao, B. et al. 2011. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav. Immun. 25:1025.
27. Sta, M., Sylva-Steenland, R. M., Casula, M. et al. 2011. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol. Dis. 42:211.
28. Xu, Y., Qian, L., Zong, G. et al. 2012. Class A scavenger receptor promotes cerebral ischemic injury by pivoting microglia/macrophage polarization. Neuroscience 218:35.
29. Pokrishevsky, E., Grad, L. I., Yousefi, M., Wang, J., Mackenzie, I. R. and Cashman, N. R. 2012. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 7:e35050.
30. Cady, J., Koval, E. D., Benitez, B. A. et al. 2014. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 71:449.
31. Ischiropoulos, H. and Beckman, J. S. 2003. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111:163.
32. Barber, S. C. and Shaw, P. J. 2010. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 48:629.
33. Brown, I. R. 2007. Heat shock proteins and protection of the nervous system. Ann. N. Y. Acad. Sci. 1113:147.
34. Lo Coco, D., Veglianese, P., Allievi, E. and Bendotti, C. 2007. Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neurosci. Lett. 412:73.
35. Bianchi, M. E. and Manfredi, A. A. 2009. Immunology. Dangers in and out. Science 323:1683.
36. Liu, G. T., Hwang, C. S., Hsieh, C. H. et al. 2013. Eosinophilderived neurotoxin is elevated in patients with amyotrophic lateral sclerosis. Mediators Inflamm. 2013:421389.
37. Streit, W. J., Mrak, R. E. and Griffin, W. S. 2004. Microglia and neuroinflammation: a pathological perspective. J. Neuroinflammation. 1:14.
38. Pessac, B., Godin, I. and Alliot, F. 2001. [Microglia: origin and development]. Bull. Acad. Natl Med. 185:337; discussion 346.
39. Henkel, J. S., Engelhardt, J. I., Siklós, L. et al. 2004. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55:221.
40. Turner, M. R., Cagnin, A., Turkheimer, F. E. et al. 2004. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C]®-PK11195 positron emission tomography study. Neurobiol. Dis. 15:601.
41. Rezai-Zadeh, K., Gate, D. and Town, T. 2009. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J. Neuroimmune Pharmacol. 4:462.
42. Sargsyan, S. A., Monk, P. N. and Shaw, P. J. 2005. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 51:241.
43. Masters, S. L. and O'Neill, L. A. 2011. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. Trends Mol. Med. 17:276.
44. Malaspina, A., Kaushik, N. and de Belleroche, J. 2001. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem. 77:132.
45. Rentzos, M., Nikolaou, C., Rombos, A. et al. 2007. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 8:283.
46. Hensley, K., Fedynyshyn, J., Ferrell, S. et al. 2003. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93ASOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis. 14:74.
47. Urushitani, M. and Shimohama, S. 2001. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2:71.
48. Hensley, K., Mhatre, M., Mou, S. et al. 2006. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid. Redox Signal. 8:2075.
49. Drechsel, D. A., Estévez, A. G., Barbeito, L. and Beckman, J. S. 2012. Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotox. Res. 22:251.
50. Harraz, M. M., Marden, J. J., Zhou, W. et al. 2008. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin. Invest. 118:659.
51. Liao, B., Zhao, W., Beers, D. R., Henkel, J. S. and Appel, S. H. 2012. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 237:147.
52. D'Ambrosi, N., Finocchi, P., Apolloni, S. et al. 2009. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J. Immunol. 183:4648.
53. Gandelman, M., Peluffo, H., Beckman, J. S., Cassina, P. and Barbeito, L. 2010. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J. Neuroinflammation 7:33.
54. Yiangou, Y., Facer, P., Durrenberger, P. et al. 2006. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6:12.
55. Poloni, M., Facchetti, D., Mai, R. et al. 2000. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 287:211.
56. Schoser, B. G., Wehling, S. and Blottner, D. 2001. Cell death and apoptosis-related proteins in muscle biopsies of sporadic amyotrophic lateral sclerosis and polyneuropathy. Muscle Nerve 24:1083.
57. Petri, S., Kiaei, M., Wille, E., Calingasan, N. Y. and Flint Beal, M. 2006. Loss of Fas ligand-function improves survival in G93Atransgenic ALS mice. J. Neurol. Sci. 251:44.
58. Casula, M., Iyer, A. M., Spliet, W. G. et al. 2011. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 179:233.
59. Zhao, W., Beers, D. R., Henkel, J. S. et al. 2010. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 58:231.
60. Ilzecka, J. 2008. Decreased serum-soluble TRAIL levels in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 117:343.
61. Goldknopf, I. L., Sheta, E. A., Bryson, J. et al. 2006. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem. Biophys. Res. Commun. 342:1034.
62. Humayun, S., Gohar, M., Volkening, K. et al. 2009. The complement factor C5a receptor is upregulated in NFL-/-mouse motor neurons. J. Neuroimmunol. 210:52.
63. Woodruff, T. M., Lee, J. D. and Noakes, P. G. 2014. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc. Natl Acad. Sci. U.S.A. 111:E3.
64. Keizman, D., Rogowski, O., Berliner, S. et al. 2009. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 119:383.
65. Wolbink, G. J., Brouwer, M. C., Buysmann, S., ten Berge, I. J. and Hack, C. E. 1996. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J. Immunol. 157:473.
66. Süssmuth, S. D., Sperfeld, A. D., Hinz, A. et al. 2010. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 74:982.
67. Ilzecka, J. 2009. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 120:119.
68. Alexianu, M. E., Kozovska, M. and Appel, S. H. 2001. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57:1282.
69. Tanaka, M., Kikuchi, H., Ishizu, T. et al. 2006. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 65:816.
70. Henkel, J. S., Beers, D. R., Zhao, W. and Appel, S. H. 2009. Microglia in ALS: the good, the bad, and the resting. J. Neuroimmune Pharmacol. 4:389.
71. Chiu, I. M., Phatnani, H., Kuligowski, M. et al. 2009. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc. Natl Acad. Sci. U.S.A. 106:20960.
72. Chiu, I. M., Chen, A., Zheng, Y. et al. 2008. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl Acad. Sci. U.S.A. 105:17913.
73. Rentzos, M., Evangelopoulos, E., Sereti, E. et al. 2011. Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol. Scand. 125:260.
74. Fiala, M., Chattopadhay, M., La Cava, A. et al. 2010. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflammation. 7:76.
75. Appel, S. H., Zhao, W., Beers, D. R. and Henkel, J. S. 2011. The microglial-motoneuron dialogue in ALS. Acta Myol. 30:4.
76. Rentzos, M., Rombos, A., Nikolaou, C. et al. 2010. Interleukin-15 and interleukin-12 are elevated in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur. Neurol. 63:285.
77. Ono, S., Hu, J., Shimizu, N., Imai, T. and Nakagawa, H. 2001. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J. Neurol. Sci. 187:27.
78. Butovsky, O., Siddiqui, S., Gabriely, G. et al. 2012. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 122:3063.
79. Italiani, P., Carlesi, C., Giungato, P. et al. 2014. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J. Neuroinflammation 11:94.
80. Shi, N., Kawano, Y., Tateishi, T. et al. 2007. Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate. J. Neuroimmunol. 182:232.
81. Rentzos, M., Rombos, A., Nikolaou, C. et al. 2010. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol. Scand. 122:425.
82. Houi, K., Kobayashi, T., Kato, S., Mochio, S. and Inoue, K. 2002. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 106:299.
83. Beers, D. R., Henkel, J. S., Zhao, W., Wang, J. and Appel, S. H. 2008. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl Acad. Sci. U.S.A. 105:15558.
84. Zhao, W., Xie, W., Xiao, Q., Beers, D. R. and Appel, S. H. 2006. Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J. Neurochem. 99:1176.
85. Holmøy, T., Roos, P. M. and Kvale, E. Ø. 2006. ALS: cytokine profile in cerebrospinal fluid T-cell clones. Amyotroph. Lateral Scler. 7:183.
86. Lopez-Lopez, A., Gamez, J., Syriani, E. et al. 2014. CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis. PLoS One 9:e96528.
87. Dobrowolny, G., Giacinti, C., Pelosi, L. et al. 2005. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 168:193.
88. Zhao, W., Beers, D. R., Liao, B., Henkel, J. S. and Appel, S. H. 2012. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokinemediated mechanisms. Neurobiol. Dis. 48:418.
89. Mantovani, S., Garbelli, S., Pasini, A. et al. 2009. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 210:73.
90. Beers, D. R., Henkel, J. S., Zhao, W. et al. 2011. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134:1293.
91. Kipnis, J., Avidan, H., Caspi, R. R. and Schwartz, M. 2004. Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc. Natl Acad. Sci. U.S.A. 101:14663.
92. Zlokovic, B. V. 2011. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12:723.
93. Winkler, E. A., Sengillo, J. D., Sullivan, J. S., Henkel, J. S., Appel, S. H. and Zlokovic, B. V. 2013. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 125:111.
94. Graber, D. J., Hickey, W. F. and Harris, B. T. 2010. Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J. Neuroinflammation. 7:8.
95. Fischer, L. R., Culver, D. G., Tennant, P. et al. 2004. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185:232.
96. Dupuis, L. and Loeffler, J. P. 2009. Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr. Opin. Pharmacol. 9:341.
97. Hensley, K., Abdel-Moaty, H., Hunter, J. et al. 2006. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J. Neuroinflammation. 3:2.
98. Ilzecka, J. 2003. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 108:125.
99. Troost, D., van den Oord, J. J., de Jong, J. M. and Swaab, D. F. 1989. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin. Neuropathol. 8:289.
100. Troost, D., Van den Oord, J. J. and Vianney de Jong, J. M. 1990. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 16:401.
101. Hensley, K., Floyd, R. A., Gordon, B. et al. 2002. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82:365.
102. Troost, D., Das, P. K., van den Oord, J. J. and Louwerse, E. S. 1992. Immunohistological alterations in muscle of patients with amyotrophic lateral sclerosis: mononuclear cell phenotypes and expression of MHC products. Clin. Neuropathol. 11:115.
103. Mehanna, R., Patton, E. L., Jr, Phan, C. L. and Harati, Y. 2012. Amyotrophic lateral sclerosis with positive anti-acetylcholine receptor antibodies. Case report and review of the literature. J. Clin. Neuromuscul. Dis. 14:82.
104. Tzartos, J. S., Zisimopoulou, P., Rentzos, M. et al. J. 2014. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann. Clin. Transl Neurol. 1:80.
105. Pagani, M. R., Gonzalez, L. E. and Uchitel, O. D. 2011. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol. Res. Int. 2011:497080.
106. Palma, E., Inghilleri, M., Conti, L. et al. 2011. Physiological characterization of human muscle acetylcholine receptors from ALS patients. Proc. Natl Acad. Sci. U.S.A. 108:20184.
107. Scicchitano, B. M., Rizzuto, E. and Musarò, A. 2009. Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1. Aging (Albany, NY) 1:451.
108. Miller, T. M., Kim, S. H., Yamanaka, K. et al. 2006. Gene transfer demonstrates that muscle is not a primary target for non-cellautonomous toxicity in familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. U.S.A. 103:19546.
109. Dobrowolny, G., Aucello, M., Rizzuto, E. et al. 2008. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 8:425.
110. Turner, M. R. and Modo, M. 2010. Advances in the application of MRI to amyotrophic lateral sclerosis. Expert Opin. Med. Diagn. 4:483.
111. Gonzalez, L. E., Kotler, M. L., Vattino, L. G. et al. 2011. Amyotrophic lateral sclerosis-immunoglobulins selectively interact with neuromuscular junctions expressing P/Q-type calcium channels. J. Neurochem. 119:826.
112. Pestronk, A., Adams, R. N., Clawson, L. et al. 1988. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology 38:1457.
113. Offen, D., Halevi, S., Orion, D. et al. 1998. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology 51:1100.
114. Yi, F. H., Lautrette, C., Vermot-Desroches, C. et al. 2000. In vitro induction of neuronal apoptosis by anti-Fas antibodycontaining sera from amyotrophic lateral sclerosis patients. J. Neuroimmunol. 109:211.
115. Greiner, A., Marx, A., Müller-Hermelink, H. K., Schmausser, B., Petzold, K. and Krüger, H. 1992. Vascular autoantibodies in amyotrophic lateral sclerosis. Lancet 340:378.
116. Ordoñez, G. and Sotelo, J. 1989. Antibodies against fetal muscle proteins in serum from patients with amyotrophic lateral sclerosis. Neurology 39:683.
117. Niebroj-Dobosz, I., Janik, P. and Kwieciński, H. 2004. Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes. Eur. J. Neurol. 11:13.
118. Hwang, C. S., Liu, G. T., Chang, M. D., Liao, I. L. and Chang, H. T. 2013. Elevated serum autoantibody against high mobility group box 1 as a potent surrogate biomarker for amyotrophic lateral sclerosis. Neurobiol. Dis. 58:13.
119. Puentes, F., Topping, J., Kuhle, J. et al. 2014. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 85:274.
120. Couratier, P., Yi, F. H., Preud'homme, J. L. et al. 1998. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 154:137.
121. Fialová, L., Svarcová, J., Bartos, A. et al. 2010. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 17:562.
122. Okuyama, Y., Mizuno, T., Inoue, H. and Kimoto, K. 1997. Amyotrophic lateral sclerosis with anti-acetylcholine receptor antibody. Intern. Med. 36:312.
123. Graves, M. C., Fiala, M., Dinglasan, L. A. et al. 2004. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5:213.
124. Provinciali, L., Laurenzi, M. A., Vesprini, L. et al. 1988. Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets. Acta Neurol. Scand. 78:449.
125. Engelhardt, J. I., Tajti, J. and Appel, S. H. 1993. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 50:30.
126. Calvo, A., Moglia, C., Balma, M. and Chiò, A. 2010. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? CNS Neurol. Disord. Drug Targets 9:325.
127. Saresella, M., Piancone, F., Tortorella, P. et al. 2013. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin. Immunol. 148:79.
128. Brandt, C. and Pedersen, B. K. 2010. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. J. Biomed. Biotechnol. 2010:520258.
129. Trujillo, M. E., Sullivan, S., Harten, I., Schneider, S. H., Greenberg, A. S. and Fried, S. K. 2004. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J. Clin. Endocrinol. Metab. 89:5577.
130. Yang, H., Chang, J., Chen, W. et al. 2013. Treadmill exercise promotes interleukin 15 expression in skeletal muscle and interleukin 15 receptor alpha expression in adipose tissue of high-fat diet rats. Endocrine 43:579.
131. Akerstrom, T., Steensberg, A., Keller, P., Keller, C., Penkowa, M. and Pedersen, B. K. 2005. Exercise induces interleukin-8 expression in human skeletal muscle. J. Physiol. 563:507.
132. Ilzecka, J., Stelmasiak, Z. and Dobosz, B. 2002. Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 20:239.
133. Cereda, C., Baiocchi, C., Bongioanni, P. et al. 2008. TNF and sTNFR1/2 plasma levels in ALS patients. J. Neuroimmunol. 194:123.
134. Tateishi, T., Yamasaki, R., Tanaka, M. et al. 2010. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J. Neuroimmunol. 222:76.
135. Elliott, J. L. 2001. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res. Mol. Brain Res. 95:172.
136. Xie, Y., Weydt, P., Howland, D. S., Kliot, M. and Möller, T. 2004. Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. Neuroreport. 15:2513.
137. Kuhle, J., Lindberg, R. L., Regeniter, A. et al. 2009. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 16:771.
138. Mitchell, R. M., Simmons, Z., Beard, J. L., Stephens, H. E. and Connor, J. R. 2010. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 42:95.
139. Banerjee, R., Mosley, R. L., Reynolds, A. D. et al. 2008. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One 3:e2740.
140. Henkel, J. S., Beers, D. R., Wen, S. et al. 2013. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 5:64.
141. Kipnis, J., Cardon, M., Avidan, H. et al. 2004. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J. Neurosci. 24:6133.
142. Zhang, R., Gascon, R., Miller, R. G. et al. 2005. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 159:215.
143. Zhang, R., Hadlock, K. G., Do, H. et al. 2011. Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 230:114.
144. Vargas, M. R. and Johnson, J. A. 2010. Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics 7:471.
145. Hall, E. D., Oostveen, J. A. and Gurney, M. E. 1998. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23:249.
146. Brown, R. H., Jr, Johnson, D., Ogonowski, M. and Weiner, H. L. 1987. Antineural antibodies in the serum of patients with amyotrophic lateral sclerosis. Neurology 37:152.
147. May, C., Nordhoff, E., Casjens, S. et al. 2014. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PLoS One 9:e89596.
148. van Blitterswijk, M., Gulati, S., Smoot, E. et al. 2011. Antisuperoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 12:430.
149. Soussan, L., Tchernakov, K., Bachar-Lavi, O., Yuvan, T., Wertman, E. and Michaelson, D. M. 1994. Antibodies to different isoforms of the heavy neurofilament protein (NF-H) in normal aging and Alzheimer's disease. Mol. Neurobiol. 9:83.
150. Rosenmann, H., Meiner, Z., Geylis, V., Abramsky, O. and Steinitz, M. 2006. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci. Lett. 410:90.
151. Bartos, A., Fialová, L., Soukupová, J., Kukal, J., Malbohan, I. and Pitha, J. 2007. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol. Scand. 116:100.
152. Bartos, A., Fialová, L., Soukupová, J., Kukal, J., Malbohan, I. and Pit'ha, J. 2007. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J. Neurol. 254:20.
153. Levin, E. C., Acharya, N. K., Han, M. et al. 2010. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res. 1345:221.
154. Dujmovic, I., Mader, S., Schanda, K. et al. 2011. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. J. Neuroimmunol. 234:124.
155. Fialová, L., Bartos, A., Svarcová, J. and Malbohan, I. 2011. Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS One 6:e27476.
156. Jianping, L., Zhibing, Y., Wei, Q., Zhikai, C., Jie, X. and Jinbiao, L. 2006. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20:127.
157. Colasanti, T., Barbati, C., Rosano, G., Malorni, W. and Ortona, E. 2010. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun. Rev. 9:807.
158. Fialová, L., Švarcová, J., Bartos, A. and Malbohan, I. 2012. Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiol. (Praha) 57:415.
159. Niebroj-Dobosz, I., Dziewulska, D. and Janik, P. 2006. Autoantibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS). Folia Neuropathol. 44:191.
160. Bruijn, L. I., Miller, T. M. and Cleveland, D. W. 2004. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27:723.
161. Nardo, G., Iennaco, R., Fusi, N. et al. 2013. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain 136:3305.
162. Aebischer, J., Moumen, A., Sazdovitch, V., Seilhean, D., Meininger, V. and Raoul, C. 2012. Elevated levels of IFNγ and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Eur. J. Neurol. 19:752.
163. Lu, C. H., Petzold, A., Kalmar, B., Dick, J., Malaspina, A. and Greensmith, L. 2012. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One 7:e40998.
164. Lu, C. H., Petzold, A., Topping, J. et al. 2014. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J. Neurol. Neurosurg. Psychiatry. [published online first 9 July 2014] doi:1136/jnnp-2014-307672.
165. Boillée, S., Yamanaka, K., Lobsiger, C. S. et al. 2006. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312:1389.
166. Rothstein, J. D., Patel, S., Regan, M. R. et al. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73.
167. Lepore, A. C., Rauck, B., Dejea, C. et al. 2008. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 11:1294.
168. Tada, S., Okuno, T., Yasui, T. et al. 2011. Deleterious effects of lymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateral sclerosis. J. Neuroinflammation. 8:19.
169. Meininger, V., Drory, V. E., Leigh, P. N., Ludolph, A., Robberecht, W. and Silani, V. 2009. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 10:378.
170. Glass, J. D., Boulis, N. M., Johe, K. et al. 2012. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 30:1144.
171. Karussis, D., Karageorgiou, C., Vaknin-Dembinsky, A. et al. 2010. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67:1187.
172. Smith, S. A., Miller, R. G., Murphy, J. R. and Ringel, S. P. 1994. Treatment of ALS with high dose pulse cyclophosphamide. J. Neurol. Sci. 124(Suppl):84.
173. Werdelin, L., Boysen, G., Jensen, T. S. and Mogensen, P. 1990. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 82:132.
174. Meucci, N., Nobile-Orazio, E. and Scarlato, G. 1996. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J. Neurol. 243:117.
175. Gordon, P. H., Moore, D. H., Miller, R. G. et al. 2007. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6:1045.
176. Fiala, M., Mizwicki, M. T., Weitzman, R., Magpantay, L. and Nishimoto, N. 2013. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am. J. Neurodegener. Dis. 2:129.